Found 629 clinical trials
-
Accepting Seniors
-
Accepting adults
-
An interventional trial
-
For all genders
-
Cardiology/Vascular Diseases
-
Currently Recruiting
Atrial Fibrillation
of ischemic stroke or systemic embolism in subjects with non-valvular atrial fibrillation who have an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulation.
- 618 views
- 03 Dec, 2020
- 1 location
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
An interventional trial
-
For all genders
-
Family Medicine
-
Currently Recruiting
Heart Valve Disease – Aortic and Mitral
Study Description: Multi-center, international, prospective, randomized, interventional, pre-market study. Patients will be seen at pre and post-procedure, discharge, 30 days, 6 months, 1 year, 18 months, and annually through 10 years. Randomly assigned (50% to either group) Treatment of Aortic Stenosis with either Transcatheter Aortic Valve Replacement (TAVR) device or …
- 776 views
- 05 Feb, 2021
- 1 location
-
Accepting pediatric ages
-
Accepting adults
-
For all genders
-
Currently Recruiting
ENSURE-AF
ENSURE-AF
- 62 views
- 23 Nov, 2020
- 1 location
-
Accepting Seniors
-
Accepting adults
-
For all genders
-
Cardiology/Vascular Diseases
-
Currently Recruiting
Evaluation of QDOT MICRO™ catheter for pulmonary vein isolation (PVI) in subjects with Paroxysmal Atrial Fibrillation (PAF) Protocol# BWI_2017_07
The purpose of this study is to provide information about the safety and long-term effectiveness of the QDOT MICRO™ Catheter for the treatment of subjects with Paroxysmal Atrial Fibrillation
- 51 views
- 24 Nov, 2020
- 1 location
-
For all genders
-
Currently Recruiting
nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation
nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation
- 82 views
- 23 Nov, 2020
- 1 location
-
Phase 2 trial
-
Accepting pediatric ages
-
Accepting adults
-
For all genders
-
Currently Recruiting
GENETIC-AF: A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure
GENETIC-AF: A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure
- 452 views
- 08 Nov, 2020
- 1 location
-
Accepting Seniors
-
Accepting adults
-
For all genders
-
Cardiology/Vascular Diseases
-
Currently Recruiting
Evaluation of the VISITAG SURPOINT™ Module with External Processing Unit (EPU) when used with the THERMOCOOL SMARTTOUCH® SF and the THERMOCOOL SMARTTOUCH® Catheters for Pulmonary Vein Isolation (PVI) (SURPOINT COA)
Prospective, non-randomized, post market clinical evaluation of the VISITAG SURPOINT™ Module with External Processing Unit (EPU) when used with STSF catheter and ST catheter compared to an historical control performance goal. A maximum of 330 subjects will be enrolled across up to 45 sites. Two hundred eighty (280) enrolled subjects …
- 104 views
- 24 Nov, 2020
- 1 location
-
Accepting Seniors
-
Accepting adults
-
For all genders
-
Cardiology/Vascular Diseases
-
Currently Recruiting
Assessment of the WATCHMANTM Device in Patients Unsuitable for Oral Anticoagulation ASAP-TOO
Assessment of the WATCHMANTM Device in Patients Unsuitable for Oral Anticoagulation ASAP-TOO
- 408 views
- 03 Dec, 2020
- 1 location
-
Accepting pediatric ages
-
Accepting adults
-
For all genders
-
Cardiology/Vascular Diseases
-
Currently Recruiting
Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub- Clinical Atrial fibrillation (ARTESiA)
Apixaban for the Reduction of Thrombo-Embolism in patients with Device-Detected Sub- Clinical Atrial fibrillation (ARTESiA)
- 314 views
- 24 Nov, 2020
- 1 location
-
Phase 2 trial
-
For all genders
-
Currently Recruiting
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II - ORBIT AF II - Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF II) is designed to evaluate the utilization of target-specific antithrombotic agents, such as factor Xa (FXa) inhibitors and direct thrombin inhibitors, and associated outcomes.
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II - ORBIT AF II - Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF II) is
- 88 views
- 08 Nov, 2020
- 1 location